186 related articles for article (PubMed ID: 34196768)
21. Immune checkpoint inhibitors for progressive multifocal leukoencephalopathy: Identifying relevant outcome factors.
Lambert N; El Moussaoui M; Maquet P
Eur J Neurol; 2021 Nov; 28(11):3814-3819. PubMed ID: 34251719
[TBL] [Abstract][Full Text] [Related]
22. Probable progressive multifocal leukoencephalopathy-immune reconstitution inflammatory syndrome with immunosuppressant dose reduction following lung transplantation: a case report and literature review.
Ishii K; Yamamoto F; Homma S; Okada Y; Nakamichi K; Saijo M; Tamaoka A
BMC Neurol; 2019 Oct; 19(1):263. PubMed ID: 31672142
[TBL] [Abstract][Full Text] [Related]
23. Combined Treatment With Pembrolizumab and Allogenic BK Virus-Specific T Cells in Progressive Multifocal Leukoencephalopathy: A Case Report.
Wicklein R; Heidegger S; Verbeek M; Eiz-Vesper B; Maecker-Kolhoff B; Kirschke JS; Page A; Korn T; Hemmer B; Deschauer M
Neurol Neuroimmunol Neuroinflamm; 2021 Jul; 8(5):. PubMed ID: 34285093
[TBL] [Abstract][Full Text] [Related]
24. [Targeted therapy and progressive multifocal leukoencephalopathy (PML): PML in the era of monoclonal antibody therapies].
Takao M
Brain Nerve; 2013 Nov; 65(11):1363-74. PubMed ID: 24200614
[TBL] [Abstract][Full Text] [Related]
25. Severe Progressive Multifocal Leukoencephalopathy (PML) and Spontaneous Immune Reconstitution Inflammatory Syndrome (IRIS) in an Immunocompetent Patient.
Krey L; Raab P; Sherzay R; Berding G; Stoll M; Stangel M; Wegner F
Front Immunol; 2019; 10():1188. PubMed ID: 31191548
[No Abstract] [Full Text] [Related]
26. Progressive multifocal leukoencephalopathy in the context of newer therapies in hematology and review of new treatment strategies.
Diamantopoulos PT; Kalopisis K; Tsatsou A; Efthymiou A; Giannakopoulou N; Hatzidavid S; Viniou NA
Eur J Haematol; 2022 May; 108(5):359-368. PubMed ID: 35100451
[TBL] [Abstract][Full Text] [Related]
27. Progressive Multifocal Leukoencephalopathy in Primary Immunodeficiencies.
Hadjadj J; Guffroy A; Delavaud C; Taieb G; Meyts I; Fresard A; Streichenberger N; L'Honneur AS; Rozenberg F; D'Aveni M; Aguilar C; Rosain J; Picard C; Mahlaoui N; Lecuit M; Hermine O; Lortholary O; Suarez F
J Clin Immunol; 2019 Jan; 39(1):55-64. PubMed ID: 30552536
[TBL] [Abstract][Full Text] [Related]
28. Innovative therapeutic concepts of progressive multifocal leukoencephalopathy.
Möhn N; Grote-Levi L; Hopfner F; Eiz-Vesper B; Maecker-Kolhoff B; Warnke C; Sühs KW; Wattjes MP; Höglinger GU; Skripuletz T
J Neurol; 2022 May; 269(5):2403-2413. PubMed ID: 34994851
[TBL] [Abstract][Full Text] [Related]
29. Pembrolizumab for the treatment of progressive multifocal leukoencephalopathy following anti-CD19 CAR-T therapy: a case report.
Mackenzie S; Shafat M; Roddy H; Hyare H; Neill L; Marzolini MAV; Gilhooley M; Marafioti T; Kara E; Sanchez E; Rees J; Lynch DS; Thomson K; Ardeshna KM; Laurence A; Peggs KS; O'Reilly M; Roddie C
EJHaem; 2021 Nov; 2(4):848-853. PubMed ID: 35845220
[TBL] [Abstract][Full Text] [Related]
30. Progressive Multifocal Leukoencephalopathy.
Grebenciucova E; Berger JR
Neurol Clin; 2018 Nov; 36(4):739-750. PubMed ID: 30366552
[TBL] [Abstract][Full Text] [Related]
31. Checkpoint inhibitors for the treatment of JC virus-related progressive multifocal leukoencephalopathy.
Beck ES; Cortese I
Curr Opin Virol; 2020 Feb; 40():19-27. PubMed ID: 32279025
[TBL] [Abstract][Full Text] [Related]
32. Partial recovery after severe immune reconstitution inflammatory syndrome in a multiple sclerosis patient with progressive multifocal leukoencephalopathy.
Calvi A; De Riz M; Pietroboni AM; Ghezzi L; Maltese V; Arighi A; Fumagalli GG; Jacini F; Donelli C; Comi G; Galimberti D; Scarpini E
Immunotherapy; 2014; 6(1):23-8. PubMed ID: 24341880
[TBL] [Abstract][Full Text] [Related]
33. Progressive multifocal leukoencephalopathy.
Weissert R
J Neuroimmunol; 2011 Feb; 231(1-2):73-7. PubMed ID: 20937530
[TBL] [Abstract][Full Text] [Related]
34. Progressive multifocal leukoencephalopathy in a patient with novel mutation in the RAC2 gene: a case report.
Bahrami S; Arshi S; Nabavi M; Bemanian MH; Fallahpour M; Rezaeifar A; Shokri S
J Med Case Rep; 2022 Jun; 16(1):235. PubMed ID: 35689244
[TBL] [Abstract][Full Text] [Related]
35. PD-1-inhibitor pembrolizumab for treatment of progressive multifocal leukoencephalopathy.
Möhn N; Wattjes MP; Adams O; Nay S; Tkachenko D; Salge F; Heine J; Pars K; Höglinger G; Respondek G; Stangel M; Skripuletz T; Jacobs R; Sühs KW
Ther Adv Neurol Disord; 2021; 14():1756286421993684. PubMed ID: 34035834
[TBL] [Abstract][Full Text] [Related]
36. Effectiveness of Immune Checkpoint Inhibitors in Transplant Recipients with Progressive Multifocal Leukoencephalopathy.
Medrano C; Vergez F; Mengelle C; Faguer S; Kamar N; Del Bello A
Emerg Infect Dis; 2019 Nov; 25(11):2145-2147. PubMed ID: 31625858
[TBL] [Abstract][Full Text] [Related]
37. Not a Disease of the Past: A Case Series of Progressive Multifocal Leukoencephalopathy in the Established Antiretroviral Era.
Summers NA; Kelley CF; Armstrong W; Marconi VC; Nguyen ML
AIDS Res Hum Retroviruses; 2019 Jun; 35(6):544-552. PubMed ID: 30834775
[TBL] [Abstract][Full Text] [Related]
38. The spectrum of progressive multifocal leukoencephalopathy: a practical approach.
Bartsch T; Rempe T; Leypoldt F; Riedel C; Jansen O; Berg D; Deuschl G
Eur J Neurol; 2019 Apr; 26(4):566-e41. PubMed ID: 30629326
[TBL] [Abstract][Full Text] [Related]
39. Atezolizumab Treatment for Progressive Multifocal Leukoencephalopathy.
Lambert N; Dauby S; Dive D; Sadzot B; Maquet P
Emerg Infect Dis; 2022 Jan; 28(1):253-6. PubMed ID: 34856110
[TBL] [Abstract][Full Text] [Related]
40. Progressive multifocal leukoencephalopathy in two natalizumab-treated stepsisters: An intriguing coincidence.
Bacchetta F; Mathias A; Schluep M; Du Pasquier R
Mult Scler; 2017 Feb; 23(2):300-303. PubMed ID: 28165319
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
